Vilon (Lys-Glu)

Vilon is a synthetic dipeptide, L-lysyl-L-glutamic acid (Lys-Glu), from the same St. Petersburg peptide-bioregulator program that produced Thymogen and the longer thymus preparations. It is described in that literature as an immunomodulatory and geroprotective “short peptide,” studied mainly in aged animal models and small clinical settings. Like the other compounds in this family, it has been used regionally but carries no FDA or EMA approval.

Vilon was developed by Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as part of a systematic effort to identify the shortest peptide sequences that retained the regulatory activity attributed to glandular extracts. Vilon (Lys-Glu) was proposed as one such minimal bioregulator, of interest both for immune function and for the group’s broader gerontology program. As with the rest of the family, the evidence originates almost entirely from this single tradition.

The originating literature frames Vilon as acting at the level of gene expression, proposing that short peptides can influence transcription and thereby help restore age-associated declines in immune and tissue function. Reported effects in aged-animal models include changes in immune parameters and markers the authors interpret as geroprotective. These are mechanistic hypotheses generated within one lab; the epigenetic claims in particular remain far from the level of independent confirmation that would let an outside reader treat them as established.

The published evidence is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research.

This table summarizes commonly discussed claims and how the published evidence weighs in.

In the published literature Vilon has been administered by injection in short courses, with the proposed activity attributed to signaling rather than sustained plasma levels, as expected for a rapidly hydrolyzed dipeptide. These routes have not been validated in independent controlled human trials.

Vilon is a clean example of the interpretive challenge the short-peptide bioregulators pose: a simple, defined molecule with a coherent story, an enthusiastic originating literature, and very little independent evidence to corroborate the more ambitious claims. The immune and geroprotective hypotheses are legitimately interesting, but they remain hypotheses at the level of international evidence. For readers, the useful frame is evidence lineage and replication, not mechanism enthusiasm. Vilon sits within the broader family covered in our overview of the Khavinson short peptides.